E. Kueenburg

A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.

M. Dimopoulos, E. Tholouli, R. Hájek, 2020, Clinical lymphoma, myeloma & leukemia.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

M. Dimopoulos, P. Sonneveld, K. Ramasamy, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

M. Dimopoulos, P. Sonneveld, D. Siegel, 2017, Clinical pharmacology : advances and applications.

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

M. Dimopoulos, P. Sonneveld, K. Ramasamy, 2015 .

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

A. Glasmacher, R. Hájek, H. Avet-Loiseau, 2012, Haematologica.

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

S. Jagannath, S. Lonial, P. Richardson, 2021, Blood.

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

P. Sonneveld, S. Jagannath, S. Lonial, 2020 .

P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, S. Jagannath, S. Lonial, 2021, Clinical Lymphoma, Myeloma & Leukemia.

MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis.

P. Sonneveld, N. Heyne, A. Glasmacher, 2014 .